0 Comentários
0 Compartilhamentos
6 Visualizações
0 Anterior
Pesquisar
Conheça novas pessoas, crie conexões e faça novos amigos
-
Faça Login para curtir, compartilhar e comentar!
-
Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease testsRoth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...0 Comentários 0 Compartilhamentos 6 Visualizações 0 Anterior
-
Rithm Capital (RITM) distributable earnings slip to $0.55 a share as Newrez lending volume falls 19%Rithm Capital Corp. (RITM) posted much higher GAAP profit on a swing in mortgage servicing values, but its non-GAAP earnings measure fell as funded mortgage volume dropped from the second quarter. Newrez funded $12.9 billion of mortgages in the third quarter, 19% less than in the second quarter and 21% less than a year earlier. Rithm Capital Corp. (RITM) disclosed the figure in its results for...0 Comentários 0 Compartilhamentos 7 Visualizações 0 Anterior